About Open Biosystems
Open Biosystems is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. Open Biosystems was founded in 2001 by a team of researchers who believe deeply in the power of science to improve their lives, and everyone elses, too. This conviction, coupled with their strong desire to help their customers succeed, motivates their employees and gives them their unrelenting focus on developing and delivering the best life sciences tools, support and services to their customers available in the industry today. Their business model, based on a collaborative spirit and focused on the value of product delivery, is inspired by the success of the open source movement in software. Open source has, over the span of just a few years, radically empowered small organizations and individuals by giving them the tools only big companies could previously afford. Open Biosystems aims to speed the progress of research by letting people use their technology in a manner that's substantially more flexible than that of other tools providers. Open Biosystems offers products that span Genomics, RNAi and Antibodies. Building on the rapid sharing model that is at the core of the Human Genome Project, Open Biosystems collaborates with some of the most innovative life science investigators working today. They partner with them to bring to market new products they have often pioneered the new resources in their own lab, and Open Biosystems prepares it for widespread use and then provides access to the research community. Delivery of genetic content is their most recent technological breakthrough. Recently, they brought to market the Tranz-vector system, the safest human-based lentiviral delivery technology. Further supplementing their already strong line of RNA interference (RNAi) and complementary DNA (cDNA) products, this technology provides investigators with superior delivery capabilities for high-quality cellular screening. The combination of their unique Tranz-vector system and whole genome RNAi & cDNA content enables their customers to perform drug target validation on a large scale. With their genomics resources, Open Biosystems provides the content investigators utilize to unlock the functions of human genes and their relationships to normal & disease development. They offer the most complete gene library in the industry. This novel library consists of several full length cDNA and open reading frame collections. Most prominently among these is the Mammalian Gene Collection (MGC), the industry's gold standard gene catalog. The discovery of RNA interference has revolutionized the way investigators approach the studies of gene expression, regulation and interactions, particularly as it relates to drug development. Their collaboration with Drs. Greg Hannon (CSHL) and Steve Elledge (Harvard) has led the way in the evolution of the short hairpin RNA (shRNA) technologies to provide the life science community with whole genome resources for human, mouse and rat with a multitude of technology and delivery advantages.